GlassScriptPhysician profile
Flint K Deshazo
NPI 1669474623
$18,595.44
in general payments reported to CMS, 2019-2025
65 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,318 · 2020: $2,576 · 2021: $2,905 · 2022: $2,848 · 2023: $2,829 · 2024: $2,550 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,948.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,761.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,739.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,676.77 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $1,368.61 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $1,338.33 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Amarin Pharma, INC. | $938.46 | 2019-2023 | |
| Glaxosmithkline, LLC. | $875.33 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $814.83 | 2019-2023 | Xarelto |
| Antares Pharma, INC. | $748.54 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amgen INC. | $722.98 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $582.10 | 2021-2024 | Octrode, Freestyle Libre 3, Proclaim |
| Amneal Pharmaceuticals LLC | $561.97 | 2019-2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.90 | 2020-2025 | Xifaxan |
| Corium, LLC | $294.92 | 2022-2025 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $291.84 | 2020-2021 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flint Deshazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.